Fusion biopsies, which fuse MRI technology with real-time ultrasounds, deliver important clinical advantages, including more accurate results. Although most prostate cancer experts aren’t ready to call the incorporation of MRI Technology into prostate biopsies the standard in prostate cancer imaging and diagnosis, they look forward to a day when it will be The future is bright for MRI technologists and similar occupations related to the industry.
The typical 12-core TRUS biopsy finds prostate cancer in men 27-40% of the time, leaving around 70% of men with a negative biopsy who are not necessarily free of prostate cancer. Fusion biopsies yield a much lower false-negative rate and, by using the fusion biopsy technique, clinicians will be able to target smaller abnormalities using MRI technology, in addition to being able to spot lesions in tough spots like the anterior prostate and apex.
According to Dr. Kurhanewicz, professor of radiology and biomedical imaging, urology, and pharmaceutical chemistry at UCSF, the advantage of having a MRI is that doctors are able to see the entire gland, which cuts down on the sampling errors experienced with a systematic biopsy. Although fusion biopsies take slightly longer to perform, many doctors agree that fusion biopsies may be the best choice for prostate biopsies, due to their accuracy.